Nastech schärft Weiber an - 500 Beiträge pro Seite

[Prolet]

Nastech Pharmaceuticals hat den "Muntermacher" für schlappe Damen in die Phase II gebracht.
Nebenwirkungen treten kaum auf.
Das Potential ist bei 50 Millionen frigiden Zicken allein in USA enorm.
Der eigentliche Hammer aber ist, daß mit dem gleichen Stoff
auch Erektionsprobleme bei Männern und Parkinson behandelt werden kann.
Das Mittel für die Herren der Schöpfung kommt demnächst in Phase III.
Die Parkinson-Sache steckt noch in den Kinderschuhen.
Trotz des schlechten Marktumfelds geht derzeit eine "steife Briese" durch den Kurs.
Kaufen !

Nastech Begins Phase II Trial for Female Sexual Dysfunction

HAUPPAUGE, N.Y., June 12 /PRNewswire/ -- Nastech Pharmaceutical Company Inc. announced initiation of a Phase II at-home clinical trial using a proprietary intranasal apomorphine HCI formulation for the treatment of female sexual dysfunction (``FSD``).
Nastech`s Phase II trial is designed to assess the safety and efficacy of intranasal apomorphine in increasing sexual satisfaction in women. The trial, conducted at six sites, is a randomized, double blind, placebo-controlled study. There will be 75 patients participating in the study, and each has been diagnosed with sexual dysfunction.
As many as four in 10 American women experience some form of sexual dysfunction, a figure likely to grow as the 41 million women of the baby boom era continue to grow older. Female sexual dysfunction is defined as persistent or recurring reduction of sex drive or aversion to sex, difficulty becoming aroused, inability to reach orgasm, and pain during sex. The causes of FSD are complicated and may include psychological problems such as depression, stress and fatigue. The intranasal apomorphine formulation is targeted to act on receptors in the central nervous system that may improve blood flow and produce lubricating secretions in the genital area of females, thus improving sexual arousal and intercourse.
``More than 50 million women suffer from sexual dysfunction,`` stated S. Ali Khan, M.D., Professor of Urology, State University New York at Stony Brook ``Many of these women do not seek evaluation and treatment because of self-imposed inhibitions. Nasal apomorphine may play a significant role in correcting hypoactive sexual desire because of its novel pharmacological action.``
``There is a significant unmet medical need for effective and non-invasive treatment of female sexual dysfunction,`` stated Steven C. Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer of Nastech. ``As a result of certain clinical studies for the treatment of male erectile dysfunction, we have gained valuable insight into the merits of our proprietary apomorphine formulations and view sexual dysfunction as a treatable disease affecting a vast portion of the ``over-30`` female population.``
In October 2000, at the Female Sexual Function Forum, Nastech presented Phase I pharmacokinetic data on the administration of intranasal apomorphine in 12 healthy female subjects which indicated the formulation to be safe and well tolerated. Patients were dosed from 0.10 - 0.75 mg of apomorphine nasal spray as a single intranasal dose. There were no serious adverse events, no changes in blood pressure, heart rate, or respiratory rate and no changes noted in the nasal mucosa.
Nastech is currently conducting Phase II clinical trials using intranasal apomorphine for the treatment of male erectile dysfunction. Earlier this month, the Company reported interim clinical data which indicate that an intranasal dose of apomorphine of 0.50 mg, when given 15 to 20 minutes before attempted sexual intercourse, allowed successful intercourse 80% of the time in the patients studied. A placebo intranasal dose or an intranasal dose of apomorphine of 0.25 mg allowed successful intercourse 12% and 40%, respectively. The interim results were reported in data from 122 men enrolled in the study.
Interim safety results were also reported from all studies, involving 1,073 doses of apomorphine. There were no serious adverse events reported in the study, including no observations of vomiting, hypotension, or syncope. The most frequent side effect was sleepiness (2.2%), followed by nausea (2.2%), dizziness (0.8%), and headache (0.5%).
Nastech Pharmaceutical Company Inc., recognized worldwide as a leader in nasal drug delivery technology, is dedicated to improving patient care by using Formulation Science, a systematic approach to drug development using biophysics, physical chemistry, and pharmacology to maximize therapeutic efficacy and safety, to provide new therapeutic options. Additional information on Nastech is available at http://www.Nastech.com.

Nastech Safe Harbor Statement
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statement made by the Company. These factors include, but are not limited to: (i) the Company`s ability to successfully complete product research and development, including pre-clinical and clinical studies and commercialization; (ii) the Company`s ability to obtain required governmental approvals, including product and patent approvals; (iii) the Company`s ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (iv) the Company`s ability to develop and commercialize its products before its competitors. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the Company`s research and development program. Additional factors that would cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in the Company`s filings with the Securities and Exchange Commission, including those factors discussed under the caption ``Risk Factors`` in the Company`s most recent Annual Report on Form 10-K.

[Erbse1]

Das war aber wirklich nicht nötig die Erektionsprobleme des Herrn Parkinson hier zu veröffentlichen. Das nimmt er dir bestimmt übel. Grüße Erbse1

[Prolet]

Ein Germanistikstudent.
Das es solche Zeitgenossen noch gibt.

Beim nächsten Thread werde ich mich verständlicher ausdrücken.
Versprochen !